[1] JEMAL A,IEGEL R,WARD E,et al.Cancer statistics,2007[J].CA Cancer J Clin,2007,57:43-66.
[2] LOOS M,KLEEFF J,FRIESS H,et al.Surgical treatment of pancreatic cancer[J].Ann N Y Acad Sci,2008,1138:169-180.
[3] YAMAMITSU S,KIMURA H,YAMADA Y,et al.Long-term repeatable chemotherapy for patients with advanced pancreatic cancer[J].Gan To Kagaku Ryoho 33 Suppl,2006,1:213-218.
[4] BAYRAKTAR S,ROCHA-LIMA C M.Advanced or metastatic pancreatic cancer:molecular targeted therapies[J].Mt Sinai J Med,2010,77:606-619.
[5] CENGEL K A,VOONG K R,CHANDRASEKARAN S,et al.Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells[J].Neoplasia,2007,9:341-348.
[6] LAGHI L,ORBETEGLI O,BIANCHI P,et al.Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers[J].Oncogene,2002,21:4301-4306.
[7] 桂德春,程张军,周家华.连环蛋白p120在人胰腺癌组织中的表达及其意义[J].东南大学学报:医学版,2011,30(5):683-687.
[8] 陶可涛,周家华,郑杰.ezrin和merlin基因在胰腺癌细胞中的表达及其意义[J].东南大学学报:医学版,2009,28(4):307-311. |